High-Dose Cyclophosphamide for hard-to-treat patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, a phase II result.
High-dose cyclophosphamide to treat solid refractory tumors demonstrated meaningful activity, while data to treat lymphoma remains scarce. This study aims to assess high-dose cyclophosphamide to treat relapsed or refractory lymphoma. A phase II study included adult patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, previously treated by ≥ 2 prior lines with no other available option of therapy. High-dose cyclophosphamide was given intravenously 3 g/m2 over two consecutive days and repeated once at 28 days in responding patients. Rituximab 375 mg/m2 intravenously was added in patients not refractory to anti-CD20 antibody. Forty-two patients with median age 65 [56-70] years were included. Patients had previously received a median of four lines of therapies. Tumor types were diffuse large-B cell lymphoma (n=26; 62%), indolent B-cell non-Hodgkin lymphoma (n=10; 24%) or mantle lymphoma (n=6; 14%). Hematologic and non-hematologic grade 3-4 toxicities occurred in 42 (100%) and 18 (43%) of patients, respectively. The overall response rate was 45%. One to two cycles of high-dose cyclophosphamide in hard-to-treat patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated a favorable safety and efficacy profile. This regimen could serve as a bridge to modern cellular therapy with CAR-T cell.